Abstract
BackgroundSingle-nucleotide polymorphism in the STAT4 gene was strongly associated with the risk of hepatocellular carcinoma (HCC) progression in patients chronically infected with hepatitis C virus (HCV).ObjectiveTo study the effect of STAT4 gene (rs7574865) polymorphism on HCC in complicating chronic hepatitis C.Patients and methodsOne hundred and fifty individuals were divided into three groups. The studied participants were divided into three groups. Group I: 50 apparently healthy individuals served as controls. They were completely free clinically with normal laboratory investigations, normal abdominal ultrasonography, and no history of liver and renal disease. Group II: 50 chronic HCV patients confirmed by HCV-antibodies and PCR HCV RNA analysis. Group III: 50 HCV-induced HCC patients confirmed by computed tomography and serum alpha-fetoprotein. Most of the patients are males with a mean age of 54 years. Real-time PCR analysis to determine STAT4 (rs7574865) gene polymorphism was performed on DNA extracted from all the studied participants.ResultsComparing the three studied groups, there was highly significant statistical difference regarding genotype and allele frequency distribution with a GG genotype of 20% in the control group, 46% in the HCV group, and 56% in the HCC group with a P value less than 0.001. GT genotype is 50% in the control group, 44% in the HCV group, and 38% in the HCC group. There were statistically significant differences in STAT4 (rs7574865) allele frequencies between the patient group (HCC and HCV as one group) and the control group (P < 0.001) [GG: odds ratio (OR)=9.562, 95% confidence interval (CI)=3.204–28.541, GT: OR = 3.075, 95% CI = 1.141–8.290]. Allele association study revealed a significant risk association between allele type and cancer development (OR = 3.066, 95% CI = 1.861–5.053).ConclusionThe results suggested that STAT4 (rs7574865) GG genotype is associated with HCC development in Egyptians with chronic HCV infection.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
